Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07740317) titled 'Neurocognitive Trajectories After BCMA CAR-T' on July 28.

Study Type: Observational

Primary Sponsor: Wake Forest University Health Sciences

Condition: Multiple Myeloma (MM) CART Therapy Refractory Multiple Myeloma (RRMM)

Intervention: Other: Standardized neurocognitive testing

Recruitment Status: Not recruiting

Date of First Enrollment: September 2026

Target Sample Size: 50

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/study/NCT07740317

Disclaimer: Curated by HT Syndication....